27431-62-5

Basic information

• Product Name: 4-(DIETHYLAMINO)BUTYLAMINE
• Synonyms: N,N-Diethyl-1,4-butanediamine;N(1),N(4)-diethylputrescine;4-DIETHYLAMINOBUTYLAMINE ---LIQUID---;4-(Diethylamino)butylamine ,97%;1,4-ButanediaMine, N1,N1-diethyl-;N1,N1-diethylbutane-1,4-diaMine;N1,N1-Diethyl-1,4-butanediamine;4-(DIETHYLAMINO)BUTYLAMINE
• CAS NO: 27431-62-5
• Molecular Formula: C₈H₂₀N₂
• Molecular Weight: 144.26
• EINECS: 248-456-1
• Mol File: 27431-62-5.mol

Chemical Properties

• Melting Point: 156-158 °C
• Boiling Point: 55°C/ 3mm
• Flash Point: 70.8 °C
• Appearance: /
• Density: 0.83
• Vapor Pressure: 0.466mmHg at 25°C
• Storage Temp.: under inert gas (nitrogen or Argon) at 2–8 °C
• PKA: 10.48±0.25(Predicted)
• Water Solubility: Slightly soluble in water.
• Sensitive: Air & Moisture Sensitive
• CAS DataBase Reference: 4-(DIETHYLAMINO)BUTYLAMINE(CAS DataBase Reference)
• NIST Chemistry Reference: 4-(DIETHYLAMINO)BUTYLAMINE(27431-62-5)
• EPA Substance Registry System: 4-(DIETHYLAMINO)BUTYLAMINE(27431-62-5)

Safety Data

• Hazard Codes: C,Xn
• Statements: 34-41-37/38-22
• Safety Statements: 26-36/37/39-39
• RIDADR: 2735
• HazardClass: 8
• PackingGroup: III
• Hazardous Substances Data: 27431-62-5(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
4-(DIETHYLAMINO)BUTYLAMINE is used as a chemical intermediate for the synthesis of various pharmaceutical compounds. Its unique structure allows it to be a key component in the development of drugs targeting specific biological pathways.
Used in Cancer Research:
4-(DIETHYLAMINO)BUTYLAMINE is used as a research tool for studying prostatic cancer cells. It has been found to reduce the putrescine uptake inhibitory activity, which can provide valuable insights into the development of novel therapeutic strategies against prostate cancer.
Used in Chemical Synthesis:
As a liquid organic compound with a reactive amine group, 4-(DIETHYLAMINO)BUTYLAMINE can be used as a building block in the synthesis of various organic molecules, including those with potential applications in materials science, agrochemicals, and other industries.

InChI:InChI=1/C8H20N2/c1-3-10(4-2)8-6-5-7-9/h3-9H2,1-2H3/p+2

Upstream product

• 663176-28-1 3-cyano-N,N-diethylpropanamide 
• 5336-75-4 4-(diethylamino)butyronitrile 
• 64-17-5 ethanol 
• 2315-36-8 2-Chloro-N,N-diethylacetamide 
• 1262500-36-6 tert-butyl 4-(diethylamino)butylcarbamate 
• 97020-69-4 N-(4-(N’,N’-diethylamino)butyl)phthalimide 
• 216171-51-6 ethyl 2-cyano-3-N,N-diethylcarbamoyl propanoate 
• 216171-57-2 2-cyano-3-N,N-diethylcarbamoylpropanoic acid 

Downstream Products

• 102812-53-3 3-(4-methoxy-phenyl)-2-phenyl-propionic acid-(4-diethylamino-butylamide) 
• 101780-52-3 3,4,5-trimethoxy-benzoic acid-(4-diethylamino-butylamide) 
• 16349-66-9 1,4-Bis-benzol 
• 80092-55-3 7-Chloro-1-[(E)-4-diethylamino-butylimino]-10-hydroxy-3-(4-trifluoromethyl-phenyl)-1,3,4,10-tetrahydro-2H-acridin-9-one 
• 106708-15-0 2,4-Diphenyl-cyclobutane-1,3-dicarboxylic acid bis-[(4-diethylamino-butyl)-amide]; hydrochloride 
• 104839-81-8 2,4-Diphenyl-cyclobutane-1,3-dicarboxylic acid bis-[(4-diethylamino-butyl)-amide] 
• 80092-67-7 7-Chloro-1-[(E)-4-diethylamino-butylimino]-3-(4-trifluoromethyl-phenyl)-1,3,4,10-tetrahydro-2H-acridin-9-one 
• 80092-77-9 7-Chloro-3-(2,4-dichloro-phenyl)-1-[(E)-4-diethylamino-butylimino]-1,3,4,10-tetrahydro-2H-acridin-9-one 
• 853942-77-5 3-[4-(diethylamino)butyl]-4-phenyl-4-(trichloromethyl)-3,4-dihydroquinazolin-2(1H)-one 
• 862370-79-4 N²-[4-(diethylamino)butyl]-6-(3,5-dimethoxyphenyl)pyrido[2,3-d]pyrimidine-2,7-diamine 
• 293301-19-6 3-(2,6-Dichlorophenyl)-7-fluoro-1,6-naphthyridin-2-amine 
• 862370-06-7 3-(2,6-dichloro-phenyl)-N⁷-(4-diethylamino-butyl)-[1,6]naphthyridine-2,7-diamine 

Relevant articles and documents

Novel Multitarget Directed Triazinoindole Derivatives as Anti-Alzheimer Agents

The multifaceted nature of Alzheimer's disease (AD) demands treatment with multitarget-directed ligands (MTDLs) to confront the key pathological aberrations. A novel series of triazinoindole derivatives were designed and synthesized. In vitro studies revealed that all the compounds showed moderate to good anticholinesterase activity; the most active compound 23e showed an IC50 value of 0.56 ± 0.02 μM for AChE and an IC50 value of 1.17 ± 0.09 μM for BuChE. These derivatives are also endowed with potent antioxidant activity. To understand the plausible binding mode of the compound 23e, molecular docking studies and molecular dynamics simulation studies were performed, and the results indicated significant interactions of 23e within the active sites of AChE as well as BuChE. Compound 23e successfully diminished H2O2-induced oxidative stress in SH-SY5Y cells and displayed excellent neuroprotective activity against H2O2 as well as Aβ-induced toxicity in SH-SY5Y cells in a concentration dependent manner. Furthermore, it did not show any significant toxicity in neuronal SH-SY5Y cells in the cytotoxicity assay. Compound 23e did not show any acute toxicity in rats at doses up to 2000 mg/kg, and it significantly reversed scopolamine-induced memory deficit in mice model. Additionally, compound 23e showed notable in silico ADMET properties. Taken collectively, these findings project compound 23e as a potential balanced MTDL in the evolution process of novel anti-AD drugs.

Structure-activity relationship study of hypoxia-activated prodrugs for proteoglycan-targeted chemotherapy in chondrosarcoma

Due to an abundant chondrogenic, poorly vascularized and particularly hypoxic extracellular matrix, chondrosarcoma, a malignant cartilaginous tumour, is chemo- and radio-resistant. Surgical resection with wide margins remains the mainstay of treatment. To address the lack of therapy, our strategy aims to increase anticancer drugs targeting and delivery in the tumour, by leveraging specific chondrosarcoma hallmarks: an extensive cartilaginous extracellular matrix, namely the high negative fixed charge density and severe chronic hypoxia. A dual targeted therapy for chondrosarcoma was investigated by conjugation of a hypoxia-activated prodrug (HAP) to quaternary ammonium (QA) functions which exhibit a high affinity for polyanionic sites of proteoglycans (PGs), the major components of the chondrosarcoma extracellular matrix. Based on preclinical results, an imidazole prodrug, ICF05016, was identified and provided the basis for a lead optimization study. A series of 27 QA-phosphoramide mustard conjugates, differing by the type of QA function and the length of the alkyl linker, was yielded by a common multi-step sequence involving phosphorylation of a key 2-nitroimidazole alcohol. Then, a screening was realized by surface plasmon resonance technology to assess biomolecular interactions between QA derivatives and aggrecan, the most abundant PG in chondrosarcoma. Results revealed that affinity depends more on the type of QA function, than on the linker length. Moreover, the presence of a benzyl group enhanced affinity to aggrecan. Twelve compounds were shortlisted and evaluated for antiproliferative activity (i.e., growth inhibiting concentration 50), under normoxic and hypoxic conditions using the human extraskeletal myeloid chondrosarcoma cell line (HEMC-SS). For all prodrugs, hypoxic selectivity was maintained and even increased, compared with the lead. From this study, compound 31f emerged as the most effective PG-targeted HAPs with a dissociation constant of 2.10 μM in the SPR experiment, a hypoxia cytotoxicity ratio of 24 and an efficient reductive cleavage under chemical and enzymatic conditions.

Identification and Structure–Activity Relationship Studies of Small-Molecule Inhibitors of the Methyllysine Reader Protein Spindlin1

The methyllysine reader protein Spindlin1 has been implicated in the tumorigenesis of several types of cancer and may be an attractive novel therapeutic target. Small-molecule inhibitors of Spindlin1 should be valuable as chemical probes as well as potential new therapeutics. We applied an iterative virtual screening campaign, encompassing structure- and ligand-based approaches, to identify potential Spindlin1 inhibitors from databases of commercially available compounds. Our in silico studies coupled with in vitro testing were successful in identifying novel Spindlin1 inhibitors. Several 4-aminoquinazoline and quinazolinethione derivatives were among the active hit compounds, which indicated that these scaffolds represent promising lead structures for the development of Spindlin1 inhibitors. Subsequent lead optimization studies were hence carried out, and numerous derivatives of both lead scaffolds were synthesized. This resulted in the discovery of novel inhibitors of Spindlin1 and helped explore the structure–activity relationships of these inhibitor series.

Incorporation of basic side chains into cryptolepine scaffold: Structure-antimalarial activity relationships and mechanistic studies

The synthesis of cryptolepine derivatives containing basic side-chains at the C-11 position and their evaluations for antiplasmodial and cytotoxicity properties are reported. Propyl, butyl, and cycloalkyl diamine side chains significantly increased activity against chloroquine-resistant Plasmodium falciparum strains while reducing cytotoxicity when compared with the parent compound. Localization studies inside parasite blood stages by fluorescence microscopy showed that these derivatives accumulate inside the nucleus, indicating that the incorporation of a basic side chain is not sufficient enough to promote selective accumulation in the acidic digestive vacuole of the parasite. Most of the compounds within this series showed the ability to bind to a double-stranded DNA duplex as well to monomeric hematin, suggesting that these are possible targets associated with the observed antimalarial activity. Overall, these novel cryptolepine analogues with substantially improved antiplasmodial activity and selectivity index provide a promising starting point for development of potent and highly selective agents against drug-resistant malaria parasites.

Regioselective covalent modification of hemoglobin in search of antisickling agents

Although the molecular defect in sickle hemoglobin that produces sickle cell disease has been known for decades, there is still no effective drug treatment that acts on hemoglobin itself. In this work, a series of diversely substituted isothiocyanates (R-NCS) were examined for their regioselective reaction with hemoglobin in an attempt to alter the solubility properties of sickle hemoglobin. Electrospray mass spectrometry, molecular modeling, X-ray crystallography, and conventional protein chemistry were used to study this regioselectivity and the resulting increase in solubility of the modified hemoglobin. Depending on the attached R-group, the isothiocyanates were found to react either with the Cysβ93 or the N-terminal amine of the α-chain. One of the most effective compounds in the series, 2-(N,N-dimethylamino)ethyl isothiocyanate, selectively reacts with the thiol of Cysβ93 which, in conjunction with the cationic group, was seen to perturb the local hemoglobin structure. This modified HbS shows an approximately 30% increase in solubility for the fully deoxygenated state, along with a significant increase in oxygen affinity. This compound and a related analogue appear to readily traverse the erythrocyte membrane. A discussion of the relation of these structural changes to inhibition of gelation is presented. The dual activities of increasing HbS oxygen affinity and directly inhibiting deoxy HbS polymerization, in conjunction with facile membrane traversal, suggest that these cationic isothiocyanates show substantial promise as lead compounds for development of therapeutic agents for sickle cell disease.

SUBSTITUTED (AMINOIMINOMETHYL OR AMINOMETHYL) BENZOHETEROARYL COMPOUNDS

This invention is directed to an (aminoiminomethyl or aminomethyl) benzoheteroaryl compound of formula I which is useful for inhibiting the activity of Factor Xa by combining said compound with a composition containing Factor Xa. The present invention is also directed to compositions containing compounds of the formula I, methods for their preparation, their use, such as in inhibiting the formation of thrombin or for treating a patient suffering from, or subject to, a disease state associated with a physiologically detrimental excess amount of thrombin.

A general method for the synthesis of N,N-dialkylaminobutylamines

A general method for the synthesis of N,N-dialkylaminobutylamines 4 from readily available chloroacetamides 6 is described.

Substituted sulfonamidobenzamides and method of treating arrhythmias

Novel substituted sulfonamidobenzamides are described as useful antiarrhythmic agents. Their use in the treatment of cardiac arrhythmias, especially re-entrant arrhythmias, via the prolongation of the action potential of cardiac tissue is provided. Pharmaceutical formulations containing such compounds are also disclosed.

Substituted sulfonamidobenzamides, antiarrhythmic agents and compositions thereof

Novel substituted sulfonamidobenzamides are described as useful antiarrhythmic agents. Their use in the treatment of cardiac arrhythmias, especially re-entrant arrhythmias, via the prolongation of the action potential of cardiac tissue is provided. Pharmaceutical formulations containing such compounds are also disclosed.